---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-006957"
form_type: "8-K"
ticker: "COLL"
cik: "0001267565"
company_name: "COLLEGIUM PHARMACEUTICAL, INC"
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T03:20:16.858367+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Collegium Q1 revenue up 23% to $177.8M; guides FY25 $735-750M; authorizes $25M ASR

## Summary
- Q1 net revenue $177.8M (+23% YoY); Jornay PM $28.5M (+24% Rx growth); pain portfolio $149.2M (+3%).
- GAAP net income $2.4M ($0.07 diluted EPS); non-GAAP adj. net income $57.4M ($1.49 adj. EPS).
- Adjusted EBITDA $95.2M (+3% YoY); cash & securities $197.8M, up from $162.8M at Dec 31, 2024.
- Board authorized $25M accelerated share repurchase; paid down $16.1M in debt during Q1.
- Expanded Jornay PM sales force to ~180 reps; new Chairman, board members, and execs appointed.

## SEC filing metadata
- accession: 0001558370-25-006957
- form_type: 8-K
- ticker: COLL
- cik: 0001267565
- company_name: COLLEGIUM PHARMACEUTICAL, INC
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267565/000155837025006957/0001558370-25-006957-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267565/000155837025006957/coll-20250508x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-006957
- JSON: https://secwatch.observer/filing/0001558370-25-006957.json
- Plain text: https://secwatch.observer/filing/0001558370-25-006957.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.